In this article, we will look at the 10 Best Performing American Stocks in June 2026.
June’s biggest American stock winners came during a market where investors were highly rewarding companies tied to earnings growth, AI infrastructure, cyclicals, and sector-specific catalysts.
Fidelity says “Market breadth has broadly remained strong” and “unrelenting corporate earnings growth has underpinned stocks.” That suggests some recent rallies are happening in a market still supported by profits, not just sentiment. BlackRock adds that “U.S. company earnings offered a big surprise to the upside” and that “Earnings strength is broadening,” which helps explain why investors have been willing to move beyond the usual mega-cap leaders. Capital Group also notes that markets are broadening into a “broadening opportunity set,” while stressing “active stock selection, supported by deep research.”
Against this backdrop, some of June’s best-performing American stocks may signal changing earnings expectations, renewed sector leadership, or company-specific momentum. With that in mind, let’s take a look at the 10 Best Performing American Stocks in June 2026.
Pixabay/Public Domain
Our Methodology
We used the Finviz screener to identify American stocks that rallied by at least 30% in the month of June. We then limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Insider Monkey’s quarterly newsletter strategy selects 14 small-cap and large-cap stocks every quarter and has returned 599.2% since May 2014, beating its benchmark by 372 percentage points (see more details here).
10. Moderna, Inc. (NASDAQ:MRNA)
On July 7, 2026, RBC Capital raised the firm’s price target on Moderna, Inc. (NASDAQ:MRNA) to $45 from $38 and kept a Sector Perform rating on the shares as part of a broader Q2 earnings preview for biotech. RBC said the biotech sector has gained considerable momentum, helped by strong data expanding innovative spaces and perceptions of improving FDA flexibility and stability. The firm added that Q2 earnings are shaping up to be seasonally strong, with multiple opportunities for beats and continued M&A activity.
On June 26, Piper Sandler raised the firm’s price target on Moderna, Inc. (NASDAQ:MRNA) to $77 from $69 previously and kept an Overweight rating on the shares.
On June 25, Moderna announced research and early development updates at its Science Day event. The company said it is balancing near-term growth with long-term innovation, supported by its four approved products, infectious disease launches, geographic expansion, and late-stage pipeline opportunities, including investigational intismeran autogene therapy and propionic acidemia therapeutic. Moderna also said its Scientific Intelligence Engine uses data, AI, and machine learning, automation, and robotics to accelerate discovery and improve operations.
Moderna, Inc. (NASDAQ:MRNA) provides messenger RNA medicines in the United States, Europe, and internationally.
9. Butterfly Network, Inc. (NYSE:BFLY)
On July 2, 2026, Butterfly Network, Inc. (NYSE:BFLY) announced the commercial availability of its Butterfly iQ+ and iQ3 handheld ultrasound devices and mobile application in Brazil through authorized distribution partners. John Soto, Senior Vice President of International at Butterfly Network, said meeting Brazil’s regulatory and certification requirements reflects the strength of Butterfly’s technology and its ability to bring ultrasound solutions to clinicians in markets with high standards.
On June 18, Butterfly Network provided commentary following Midjourney’s public announcement of Midjourney Medical and The Midjourney Scanner, a full-body tomographic imaging machine. The current scanner prototype incorporates 40 Butterfly Ultrasound-on-Chip imaging modules per system under a co-development agreement between the two companies. Future generations are expected to use substantially more imaging modules as the platform evolves and scales.
CEO Joseph DeVivo said Midjourney’s whole-body scanner has “no radiation, no magnetic risk, low cost, and accessible,” with about half a million sensors scanning simultaneously and over two petaflops of processing power. DeVivo said Butterfly is supporting Midjourney’s mission to democratize access to personal imaging data, and that the roadmap introduced by Founder David Holz represents a potentially meaningful commercial opportunity for Butterfly.
Butterfly Network, Inc. (NYSE:BFLY) develops, manufactures, and commercializes ultrasound imaging solutions in the United States and internationally.
Hedge Fund Resource Center